Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Topas Therapeutics GmbH. (8/22/17). "Press Release: Topas Therapeutics Signs Multi-year Research and Option Agreement with Lilly Focused on Immune Tolerance". Hamburg.

Organisations Organisation Topas Therapeutics GmbH
  Organisation 2 Eli Lilly & Co. Inc. (NYSE: LLY)
  Group Eli Lilly (Group)
Products Product immuno modulatory compound (IMO)
  Product 2 drug development
Index term Index term Lilly–Topas Therapeutics: immuno modulatory compounds, 201708– collab €na multi-y research + option agreem
Persons Person Jessen, Timm-Heinrich (Topas Therapeutics 201510– Managing Director before Bionamics + Scienamics + Evotec OAI)
  Person 2 Bumol, Thomas F. (Lilly 201708 SVP Biotechnology + Immunology Research)

> Work will utilize Topas' novel approach for antigen-specific tolerance induction

> Lilly has option to in-license and further develop drug candidates produced under the collaboration

Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private company, today announced that it has signed a multi-year agreement with Eli Lilly and Company (Lilly) to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas will be responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. Under the terms of the agreement, Lilly has an option for all candidates produced under the collaboration for in-licensing and further development. Topas will receive R&D funding and participate in the future success of any compounds in-licensed by Lilly. Financial details of the collaboration are not being disclosed.

Topas' technology platform induces antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities; peptide-loaded nanoparticles are selectively targeted towards liver sinusoidal endothelial cells (LSECs). LSECs are one of the body's premier sites to induce tolerance against bloodborne antigens by generating peptide-specific regulatory T cells.

Timm Jessen, CEO of Topas Therapeutics, said: "We are excited to be working with Lilly to generate drug candidates using our proprietary technology. We expect this work to support the value of our approach in inducing tolerance also against external antigens. Additionally, the interest from such an important pharmaceutical company in our technology, we believe, supports the strong commercial potential of our work."

Thomas F. Bumol, Ph.D., senior vice president of biotechnology and immunology research at Lilly, added: "Lilly is committed to be an innovation leader in immunology. Topas has a very novel approach to immune tolerance induction, which we would like to see successfully applied to certain disease relevant antigens. We look forward to working together with Topas on their unique platform."

About Topas Therapeutics

Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas' technology platform induces antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities. The company has two programs preparing to enter the clinic during 2018 - one for multiple sclerosis and one for an orphan disease. Topas also has a co-development program in Type 1 diabetes that is currently in pre-clinical testing. Topas' investors include: Epidarex Capital, GIMV, EMBL Ventures and Evotec.

For additional information, please visit:


Topas Therapeutics GmbH
Dr. Timm-H. Jessen
CEO / Managing Director
Falkenried 88
20251 Hamburg

Media Relations Europe
MC Services AG
Anne Hennecke
Phone +49 211 529 252 22

Media Relations U.S.
Laurie Doyle
Phone +1 339 832 0752

Record changed: 2017-08-30


Picture [LSE] – The Business Web Portal 600x60px

More documents for Topas Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top